李国豪

理论上只要有足够数量的肿瘤抗原，就可以引起抗肿瘤免疫反应。但肿瘤细胞可以通过免疫检查点，抑制T细胞激活，从而逃避免疫杀伤。因此，以免疫检查点阻断为代表的肿瘤免疫治疗正在逐步获得越来越多的临床应用。作为免疫检查点分子中的重要组成部分，B7分子家族近年来受到广泛关注。本文通过对11个已知的B7家族分子进行了介绍，从而展示了调控B7家族信号在肿瘤治疗中的巨大潜力。

免疫检查点；肿瘤治疗；B7家族

[1]任军, 黄红艳, HONGYAN H. 靶向免疫检查点的肿瘤免疫治疗现状与趋势 [J]. 中国肿瘤临床, 2014: 415-9. [2]CHAPOVAL A I, CHAPOVAL S P, SHCHERBAKOVA N S, et al. Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors [J]. Russian Journal of Bioorganic Chemistry, 2019, 45(5): 321-34. [3]HAN Y, LIU D, LI L. PD-1/PD-L1 pathway: current researches in cancer [J]. Am J Cancer Res, 2020, 10(3): 727-42. [4]ESENSTEN J H, HELOU Y A, CHOPRA G, et al. CD28 Costimulation: From Mechanism to Therapy [J]. Immunity, 2016, 44(5): 973-88. [5]SOLINAS C, GU-TRANTIEN C, WILLARD-GALLO K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy [J]. ESMO Open, 2020, 5(1). [6]LIU C, ZHANG G, XIANG K, et al. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy [J]. Cancer Immunol Immunother, 2021. [7]LEONG S R, LIANG W C, WU Y, et al. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer [J]. Mol Pharm, 2015, 12(6): 1717-29. [8]WANG L, RUBINSTEIN R, LINES J L, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses [J]. J Exp Med, 2011, 208(3): 577-92. [9]BRANDT C S, BARATIN M, YI E C, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans [J]. J Exp Med, 2009, 206(7): 1495-503.

点击下载PDF